In-vitro anti-diabetic activity and in-silico studies of binding energies of palmatine with alpha-amylase, alpha-glucosidase and DPP-IV enzymes

Patrick Okechukwu,Mridula Sharma,Wen Hui Tan,Hor Kuan Chan,Kavita Chirara,Anand Gaurav,Mayasah Al-Nema
DOI: https://doi.org/10.3897/pharmacia.67.e58392
2020-11-27
Pharmacia
Abstract:Palmatine a protoberberine alkaloid has been previously reported to possess in vivo antidiabetic and antioxidant property. The aim of the experiment is to evaluate the in vitro antidiabetic activity and in-silico studies of the binding energies of Palmatine, acarbose, and Sitagliptin with the three enzymes of alpha-amylase, alpha-glucosidase, and dipeptidyl peptidase-IV (DPP-IV). The in vitro antidiabetic study was done by evaluating the inhibitory effect of palmatine on the activities of alpha-amylase, alpha-glucosidase, and DPP-IV. Acarbose, and sitagliptin was used as standard drug. The molecular docking study was performed to study the binding interactions of palmatine with alpha-glucosidase, a-amylase, and DPP-IV. The binding interactions were compared with the standard compounds Sitagliptin and acarbose. Palmatine with IC 50 (1.31 ± 0.27 μM) showed significant difference of (< 0.0001) higher inhibiting effect on alpha-amylase and weak inhibiting effect on alpha-glucosidase enzyme with IC 50 (9.39 ± 0.27 μM) and DPP-IV with IC 50 (8.7 ± 1.82 μM). Palmatine possess inhibition effect on the three enzymes.
What problem does this paper attempt to address?